aap Implantate AG (XETRA: AAQ.DE) announced today that the United States Patent and Trademark Office (USPTO) has issued the notice of allowance for aap´s silver coating patent.
This notice represents a significant advancement in aap’s strategy to build a coherent trauma portfolio which addresses broad indications as well as unmet customers’ needs. The fundamental nature of this technology lies in the property of silver as a coating material for medical devices to prevent biofilm formation and hence reduce infection risk. aap’s silver coating as a platform technology can be applied not only to the existing trauma portfolio but also for other orthopedic implants. Such a technology which aims to reduce infection rates directly contributes to improved patient care and represents a major step in saving healthcare costs.
Bruke Seyoum Alemu, COO, comments: “We are excited about this advancement in the development of our silver coating technology which extends our IP protected trauma portfolio. Complementing our existing LOQTEQ® portfolio, silver-coated implants will strengthen aap’s strategy to offer added-value trauma products addressing the growing infection care market. We expect to present the results of the first animal trials for local and systemic tolerability in the second quarter of 2014.”
aap plans to submit the technology for regulatory approval within 12-15 months, which would allow first EU market introduction in 2015.